San Diego-based biopharmaceuticals company Ambit Biosciences has shuffled its board this morning, saying it has added Jeffrey S. Hatfield as a member of its board of directors, as current board member Steven Elms resigns. Hatfield is the CEO and is on the baord of Vitae Pharmaceuticals, and also has served at Bristol-Myers Squibb. The company did not say why Elms resigned, but said Hatfield is a direct replacement for Elms in that position. Ambit is focused on oncology, autoimmune and inflammatory diseases.
Top NewsWednesday, June 4, 2014
Ambit Biosciences Shuffles Board